Home > Insider Trading > Filing (0000950170-25-023625)

Filing Details

Accession Number:: 0000950170-25-023625
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-02-19 20:48:57
Reporting Period:: 2025-02-16

Filing Date:: 2025-02-19
Accepted Time:: 2025-02-19 20:48:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1743881	Bridgebio Pharma Inc.	BBIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1742485	Neil Kumar	C/O Bridgebio Pharma, Inc. 3160 Porter Dr., Suite 250 Palo Alto CA 94304	Chief Executive Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-02-16	55,539	$0.00	267,257	No	4	M	Direct
Common Stock	Disposition	2025-02-16	23,996	$34.90	243,261	No	4	F	Direct
Common Stock	Disposition	2025-02-19	31,467	$36.14	211,794	No	4	S	Direct
Common Stock	Disposition	2025-02-19	76	$36.56	211,718	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2025-02-16	2,395	$0.00	2,395	$0.00
Common Stock	Restricted Stock Units	Disposition	2025-02-16	33,544	$0.00	33,544	$0.00
Common Stock	Restricted Stock Units	Disposition	2025-02-16	19,600	$0.00	19,600	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	No	4	M	Direct
268,352	No	4	M	Direct
235,191	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,098,447	Indirect	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Common Stock	995,686	Indirect	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)

Footnotes

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax obligation in connection with the vesting of 55,539 shares of Common Stock underlying the Reporting Person's RSUs.
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
Represents the weighted average sale price of the shares sold from $35.50 to $36.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vested on a quarterly basis. The RSUs have no expiration date.
The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.